Trial · NCT04379596

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

NCT04379596, Phase 2, Active not recruiting, AstraZeneca

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03). Trials, record NCT04379596. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04379596

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
NCT number: NCT04379596
Status: Active not recruiting
Phases: Phase 2
Enrollment: 452 participants, actual
Lead sponsor: AstraZeneca
Conditions: Gastric Cancer
Interventions: Fluorouracil (5-FU), Capecitabine, Durvalumab, Oxaliplatin, Trastuzumab, Trastuzumab deruxtecan, Cisplatin, Pembrolizumab, Volrustomig, Rilvegostomig
First posted: 2020-05-07
Last updated: 2026-08-28
Other registries' IDs: eudract:2019-004483-22

Source ClinicalTrials.gov

Registered outcomes25

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Part 1: Occurrence of adverse events (AEs) and serious adverse events (SAEs), graded according to NCI CTCAE v5.0	Safety will be assessed up to the follow-up period, approximately 24 months.	Occurrence of AEs and SAEs graded according to NCI CTCAE v5.0
Primary	Part 1: Ocurrence of dose-limiting toxicities (DLTs)	Safety will be assessed up to the follow-up period, approximately 24 months.	Occurrence of dose limiting toxicities
Primary	Part 1: Changes from baseline in laboratory parameters	Safety will be assessed up to the follow-up period, approximately 24 months.	Changes in laboratory parameters (every in appropriate units) compared to baseline results.
Primary	Part 1: Changes from baseline in vital signs	Safety will be assessed up to the follow-up period, approximately 24 months.	Changes in vital signs results compared to baseline results.
Primary	Part 1: Changes from baseline in electrocardiogram (ECG) results	Safety will be assessed up to the follow-up period, approximately 24 months.	Changes in ECG results compared to baseline results.
Primary	Part 2, Part 3, Part 4 and Part 5: Endpoint assessed by Investigator per RECIST v1.1: Confirmed Objective Response Rate (ORR)	(Endpoint: ORR) Efficacy will be assessed at an average of approximately 12 months	Confirmed ORR per RECIST 1.1 is the percentage of patients with Complete Response or Partial Response that is subsequently confirmed.
Secondary	Part 1: Objective Response Rate (ORR)	Efficacy will be assessed at an average of approximately 12 months	Confirmed ORR per RECIST 1.1 is the percentage of patients with Complete Response or Partial Response that is subsequently confirmed.
Secondary	Part 2, Part 3, Part 4 and Part 5: Occurrence of adverse events (AEs) and serious adverse events (SAEs)	Safety will be assessed up to follow-up period, approximately 24 months	Occurrence of AEs and SAEs graded according to NCI CTCAE v5.0
Secondary	Part 2, Part 3, Part 4 and Part 5: Changes from baseline in laboratory parameters	Safety will be assessed up to follow-up period, approximately 24 months	Changes in laboratory parameters (every in appropriate units) compared to baseline results.
Secondary	Part 2, Part 3, Part 4 and Part 5: Changes from baseline in vital signs	Safety will be assessed up to follow-up period, approximately 24 months	Changes in vital signs results compared to baseline results.

1 to 10 of 25Source ClinicalTrials.gov

See all 25 registered outcomes

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
40341124	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT04379596

GET https://conductscience.org/api/trials/v1/NCT04379596/registered?page=2

API reference For AI assistants